Trials / Terminated
TerminatedNCT03052725
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 391 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and older with severe eosinophilic asthma who completed the treatment period of a placebo-controlled Phase 3 trial of sc reslizumab. The study consists of a screening/baseline visit followed by a 36-week OL treatment period and a 15-week follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | reslizumab | Reslizumab was provided in a pre-filled syringe. |
Timeline
- Start date
- 2017-03-10
- Primary completion
- 2018-02-22
- Completion
- 2018-02-22
- First posted
- 2017-02-14
- Last updated
- 2022-12-14
- Results posted
- 2019-03-21
Locations
134 sites across 13 countries: United States, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Poland, Romania, Russia, Spain, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03052725. Inclusion in this directory is not an endorsement.